+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer Drugs Market Research Reports

Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 - Product Thumbnail Image

Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • Report
  • April 2021
From
Doxorubicin Market Research Report by Drug Formulation, by Application, by Distribution Channel, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Product Thumbnail Image

Doxorubicin Market Research Report by Drug Formulation, by Application, by Distribution Channel, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • Report
  • January 2022
  • 203 Pages
From
Doxorubicin Market Research Report by Drug Formulation, by Application, by Distribution Channel, by State - United States Forecast to 2027 - Cumulative Impact of COVID-19 - Product Thumbnail Image

Doxorubicin Market Research Report by Drug Formulation, by Application, by Distribution Channel, by State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • Report
  • January 2022
  • 103 Pages
From
Metastatic Breast Cancer Treatment Market Research Report by Treatment Type, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Product Thumbnail Image

Metastatic Breast Cancer Treatment Market Research Report by Treatment Type, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • Report
  • January 2022
  • 190 Pages
From
Methotrexate (CAS 59-05-2) Global Market Research Report 2021 - Product Thumbnail Image

Methotrexate (CAS 59-05-2) Global Market Research Report 2021

  • Report
  • January 2022
  • 50 Pages
ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
From
Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
From
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
Trastuzumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Trastuzumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 125 Pages
From
HER2-Negative Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

HER2-Negative Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
From
Metastatic triple-negative breast cancer (mTNBC) - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Metastatic triple-negative breast cancer (mTNBC) - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
From
ERBB 2 receptor antagonists - Pipeline Insight, 2022 - Product Thumbnail Image

ERBB 2 receptor antagonists - Pipeline Insight, 2022

  • Drug Pipelines
  • January 2022
  • 80 Pages
From
Inflammatory breast cancer - Epidemiology Forecast - 2032 - Product Thumbnail Image

Inflammatory breast cancer - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
From
Metastatic triple-negative breast cancer (mTNBC)- Epidemiology Forecast - 2032 - Product Thumbnail Image

Metastatic triple-negative breast cancer (mTNBC)- Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
From
Inflammatory Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Inflammatory Breast Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
From
HER2Negative Metastatic Breast Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

HER2Negative Metastatic Breast Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
Advanced Breast Cancer In Premenopausal Women - Epidemiology Forecast - 2032 - Product Thumbnail Image

Advanced Breast Cancer In Premenopausal Women - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
From
Triple Negative Breast Cancer (TNBC) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Triple Negative Breast Cancer (TNBC) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
HER2-Negative Breast Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

HER2-Negative Breast Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
HER2-Positive Breast Cancer - Epidemiology Forecast to 2032 - Product Thumbnail Image

HER2-Positive Breast Cancer - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
From
Loading Indicator

Over a million women worldwide are diagnosed with breast cancer annually. Alongside surgery, radiotherapy and immunotherapy, pharmaceutical products (including hormonal therapy and chemotherapy) are in the frontline against this terrible disease. Market reports in this section enable buyers to read up on the latest breast cancer drug pipelines and R&D strategies, as well as the medical and commercial activities of major players and niche operators such Abraxis Bioscience, Aeterna Zentaris, Agendia BV, Aphton Corp, Array BioPharma, AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly, Genentech, Genta, Novartis AG, Pfizer, Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics, and ViRexx Medical. Also included are cutting edge academic journals and various expert textbooks for medical professionals involved in breast cancer treatment. Show Less Read more